Department of Information Services, Northwell Health, New Hyde Park, NY, USA.
Donald and Barbara School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, NY, USA.
Brief Bioinform. 2020 Jul 15;21(4):1182-1195. doi: 10.1093/bib/bbz059.
Sepsis is a series of clinical syndromes caused by the immunological response to infection. The clinical evidence for sepsis could typically attribute to bacterial infection or bacterial endotoxins, but infections due to viruses, fungi or parasites could also lead to sepsis. Regardless of the etiology, rapid clinical deterioration, prolonged stay in intensive care units and high risk for mortality correlate with the incidence of sepsis. Despite its prevalence and morbidity, improvement in sepsis outcomes has remained limited. In this comprehensive review, we summarize the current landscape of risk estimation, diagnosis, treatment and prognosis strategies in the setting of sepsis and discuss future challenges. We argue that the advent of modern technologies such as in-depth molecular profiling, biomedical big data and machine intelligence methods will augment the treatment and prevention of sepsis. The volume, variety, veracity and velocity of heterogeneous data generated as part of healthcare delivery and recent advances in biotechnology-driven therapeutics and companion diagnostics may provide a new wave of approaches to identify the most at-risk sepsis patients and reduce the symptom burden in patients within shorter turnaround times. Developing novel therapies by leveraging modern drug discovery strategies including computational drug repositioning, cell and gene-therapy, clustered regularly interspaced short palindromic repeats -based genetic editing systems, immunotherapy, microbiome restoration, nanomaterial-based therapy and phage therapy may help to develop treatments to target sepsis. We also provide empirical evidence for potential new sepsis targets including FER and STARD3NL. Implementing data-driven methods that use real-time collection and analysis of clinical variables to trace, track and treat sepsis-related adverse outcomes will be key. Understanding the root and route of sepsis and its comorbid conditions that complicate treatment outcomes and lead to organ dysfunction may help to facilitate identification of most at-risk patients and prevent further deterioration. To conclude, leveraging the advances in precision medicine, biomedical data science and translational bioinformatics approaches may help to develop better strategies to diagnose and treat sepsis in the next decade.
脓毒症是一系列由感染引起的免疫反应导致的临床综合征。脓毒症的临床证据通常归因于细菌感染或细菌内毒素,但病毒、真菌或寄生虫感染也可能导致脓毒症。无论病因如何,快速的临床恶化、长时间在重症监护病房停留和高死亡率都与脓毒症的发生率相关。尽管脓毒症很普遍且发病率高,但脓毒症结局的改善仍然有限。在这篇全面的综述中,我们总结了脓毒症风险评估、诊断、治疗和预后策略的现状,并讨论了未来的挑战。我们认为,现代技术的出现,如深度分子谱分析、生物医学大数据和机器智能方法,将增强脓毒症的治疗和预防。作为医疗保健提供的一部分产生的异构数据的数量、多样性、准确性和速度,以及生物技术驱动的治疗和伴随诊断的最新进展,可能为识别最易患脓毒症的患者并在更短的周转时间内减轻患者的症状负担提供新一波方法。利用现代药物发现策略(包括计算药物再定位、细胞和基因治疗、基于规律成簇间隔短回文重复序列的基因编辑系统、免疫疗法、微生物组恢复、基于纳米材料的治疗和噬菌体治疗)开发新型疗法,可能有助于开发针对脓毒症的治疗方法。我们还提供了潜在的新脓毒症靶点的经验证据,包括 FER 和 STARD3NL。实施使用实时收集和分析临床变量的基于数据的方法来跟踪、追踪和治疗与脓毒症相关的不良结局将是关键。了解脓毒症及其合并症的根源和途径,这些合并症会使治疗结果复杂化并导致器官功能障碍,可能有助于识别最易受影响的患者并防止病情进一步恶化。总之,利用精准医学、生物医学数据科学和转化生物信息学方法的进展,可能有助于在未来十年内开发更好的脓毒症诊断和治疗策略。